Canada markets open in 1 hour 4 minutes

PharmaCyte Biotech, Inc. (PMCB)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.1400+0.0400 (+1.90%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 18.09M
Enterprise Value -25.60M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.58
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -9.23

Trading Information

Stock Price History

Beta (5Y Monthly) -0.13
52-Week Change 3-31.41%
S&P500 52-Week Change 328.04%
52 Week High 33.2300
52 Week Low 31.9200
50-Day Moving Average 32.2082
200-Day Moving Average 32.2208

Share Statistics

Avg Vol (3 month) 324.7k
Avg Vol (10 day) 36.02k
Shares Outstanding 58.45M
Implied Shares Outstanding 68.54M
Float 88.07M
% Held by Insiders 18.12%
% Held by Institutions 113.75%
Shares Short (Apr 30, 2024) 413.01k
Short Ratio (Apr 30, 2024) 40.8
Short % of Float (Apr 30, 2024) 40.17%
Short % of Shares Outstanding (Apr 30, 2024) 40.15%
Shares Short (prior month Mar 28, 2024) 445.73k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:1550
Last Split Date 3Jul 12, 2021

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr 30, 2023
Most Recent Quarter (mrq)Jan 31, 2024

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-5.24%
Return on Equity (ttm)-1.73%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-14.82M
Diluted EPS (ttm)-1.4800
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)61.21M
Total Cash Per Share (mrq)7.23
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)27.34
Book Value Per Share (mrq)3.68

Cash Flow Statement

Operating Cash Flow (ttm)-2.11M
Levered Free Cash Flow (ttm)-1.93M